Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT06484153 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial
NCT06484153 · ClinicalTrials.gov record · last posted 2026-08-18

Fruquintinib and Pirfenidone in Combination With Anti-PD-1 Antibody in Advanced or Metastatic pMMR/MSS Colorectal Carcinoma

StatusRecruiting
PhasePhase 2
Started2024-07-22
View on ClinicalTrials.gov ↗
from the ClinicalTrials.gov record
The purpose of this study is to evaluate the efficacy and safety of fruquintinib and pirfenidone in combination with anti-PD-1 antibody in patients with standard treatment failure of advanced or metastatic pMMR/MSS colorectal adenocarcinoma.

Protocol amendment history 2 changes detected by DataLookout

2026-08-19
notable
Recruitment opened
2026-08-19
notable
Phase changed: Phase 1/2 → Phase 2
Trial Details
NCT Number NCT06484153
Lead Sponsor Union Hospital, Tongji Medical College, Huazhong University of Science and Technology
Conditions To Evaluate the Efficacy of Fruquintinib and Pirfenidone in Combination With Anti-PD-1 Antibody in Colorectal Carcinoma, To Evaluate Whether Pirfenidone Can Reshape the Tumor Microenvironment in Colorectal Cancer, Combination of Fruquintinib and Anti-PD-1 Antibody Was Reported to Improve Patient Prognosis in Colorectal Cancer
Enrollment 25 participants
Start Date 2024-07-22
Primary Completion 2026-07-22 (estimated)
Study Completion 2026-12-30 (estimated)
Updated on ClinicalTrials.gov 2026-08-18